145691-59-4

Usage

Uses

It is used in the synthesis of substituted benzylamines.

InChI:InChI=1/C7H6Br2O/c8-6-1-5(4-10)2-7(9)3-6/h1-3,10H,4H2

Upstream product

• 56908-88-4 3,5-dibromobenzyl bromide 
• 56990-02-4 3,5-dibromobenzaldehyde 
• 618-58-6 3,5-dibromobenzoic acid 
• 626-39-1 1,3,5-trisbromobenzene 
• 67973-33-5 3,5-dibromobenzoic acid ethyl ester 

Downstream Products

• 225932-11-6 1,3-Dibromo-5-(methoxymethoxymethyl)benzene 
• 225932-12-7 1,3-Dibromo-5-hexyloxymethylbenzene 
• 752224-60-5 [3,5-bis-(pyridin-3-ylethynyl)phenyl]methanol 
• 757248-89-8 ((3,5-dibromobenzyl)oxy)triisopropylsilane 
• 422569-56-0 3,5-bis(3-hydroxyprop-1-ynyl)benzaldehyde 
• 74337-30-7 1,3-dibromo-5-(chloromethyl)benzene 
• 868835-06-7 [4-(3,5-dibromobenzyloxy)-2-methylphenoxy]acetic acid methyl ester 
• 1391994-26-5 C₄₂H₆₀Br₂S₂ 
• 1391994-27-6 C₄₃H₆₀Br₂OS₂ 
• 1391994-28-7 C₄₇H₆₂OS₂ 
• 363622-48-4 1,3-dibromo-5-[(diethylphosphonyl)methyl]benzene 
• 51329-15-8 methyl 3,5-dibromobenzoate 
• 1581719-78-9 9,9'-(5-(((4-vinylbenzyl)oxy)methyl)-1,3-phenylene)bis(9Hcarbazole) 

Relevant academic research and scientific papers

Oxidized graphitic carbon nitride as a sustainable metal-free catalyst for hydrogen transfer reactions under mild conditions

The development of green and sustainable transfer hydrogenation protocols without the use of expensive noble metals and toxic solvents is a challenging task. Herein, a highly stable, low-cost, metal-free heterogeneous catalyst, oxidized graphitic carbon nitride (O-GCN), has been developed, which exhibits efficient catalytic hydrogen transfer reactions of carbonyl compounds to corresponding alcohols under mild reaction conditions. The heterogeneous catalyst was synthesized by the chemical oxidation of graphitic carbon nitride (GCN) nanosheets, which results in the generation of carboxyl, hydroxyl and ketone groups over the GCN surface. These hydrophilic groups functionalized on the surface of O-GCN nanosheets act as catalytically active sites for the hydrogen transfer reactions of carbonyl compounds. A wide range of substrates was investigated for the hydrogen transfer reactions using 2-propanol both as a hydrogen donor and a solvent. The O-GCN nanosheets resulted in high yields and high turnover numbers (TON) demonstrating the versatile catalytic potential of the as-synthesized catalyst. The detailed optimization of the reaction parameters (temperature, time and catalyst amount) was performed, in addition to the calculation of green metric parameters. Moreover, the catalyst could be easily recovered and was used for five runs without any significant loss in catalytic activity. This study provides a green, sustainable, attractive, and useful methodology for the hydrogen transfer reactions of a wide range of carbonyl compounds.

Fullerohelicates: A new class of fullerene-containing supermolecules

A multicomponent array made of a bis-copper(I) helicate core and two peripheral fullerene subunits has been prepared and electron transfer from the photoexcited Cu(I)-complexed unit to C60 occurs.

IMIDAZOLIDINONE DERIVATIVES AS INHIBITORS OF PERK

The invention is directed to substituted imidazolidinone derivatives. Specifically, the invention is directed to compounds according to Formula I (I) wherein R1, R2, R3, R4, R5, R6, R7, X, Y1, Y2 and Z are defined herein. The compounds of the invention are inhibitors of PERK and can be useful in the treatment of cancer, pre-cancerous syndromes, as Alzheimer's disease, neuropathic pain, spinal cord injury, traumatic brain injury, ischemic stroke, stroke, Parkinson disease, diabetes, metabolic syndrome, metabolic disorders, Huntington's disease, Creutzfeldt-Jakob Disease, fatal familial insomnia, Gerstmann-Str?ussler-Scheinker syndrome, and related prion diseases, amyotrophic lateral sclerosis, progressive supranuclear palsy, myocardial infarction, cardiovascular disease, inflammation, organ fibrosis, chronic and acute diseases of the liver, fatty liver disease, liver steatosis, liver fibrosis, chronic and acute diseases of the lung, lung fibrosis, chronic and acute diseases of the kidney, kidney fibrosis, chronic traumatic encephalopathy (CTE), neurodegeneration, dementias, frontotemporal dementias, tauopathies, Pick's disease, Neimann-Pick's disease, amyloidosis, cognitive impairment, atherosclerosis, ocular diseases, arrhythmias, in organ transplantation and in the transportation of organs for transplantation. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting PERK activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

Novel 9,9′-(1,3-phenylene)bis-9H-carbazole-containing copolymers as hole-transporting and host materials for blue phosphorescent polymer light-emitting diodes

Novel photo-crosslinkable hole-transport and host materials incorporated into multilayer blue phosphorescent polymer light-emitting diodes (Ph-PLEDs) were demonstrated in this study. The oxetane-containing copolymers, which function as hole-transport layers (HTL), could be cured by UV irradiation in the presence of a cationic photoinitiator. The composition of the two monomers was varied to yield three different hole-transporting copolymers, [Poly(9,9′-(5-(((4-(7-(4-(((3-methyloxetan-3-yl)methoxy)methyl)phenyl) octan-3-yl)benzyl)oxy)methyl)-1,3-phenylene)bis(9H-carbazole)) (P(mCP-Ox)-I, -II, and -III)]. In addition, monomer 1 was copolymerized with styrene to produce copolymer P(mCP-Ph) as a host material for bis[2-(4,6-difluorophenyl) pyridinato-C2,N](picolinato)iridium(III) (FIrpic), a blue-emitting dopant. All mCP-based copolymers displayed high glass transition temperatures (Tg) of up to 130-140 °C and triplet energies of up to 3.00 eV. The blue Ph-PLEDs exhibited a maximum external quantum efficiency of 2.55%, in addition to a luminous efficiency of 8.75 cd A-1 when using the device configuration of indium tin oxide/poly(3,4-ethylenedioxythiophene): poly(styrene sulfonate)/P(mCP-OX)-III/P(mCP-Ph):FIrpic(15 wt %)/3,3′-[5′-[3-(3-pyridinyl)phenyl][1,1′:3′, 1′′-terphenyl]-3,3′′-diyl]bispyridine/LiF/Al. The device bearing P(mCP-Ox)-III HTL, containing the highest composition of mCP unit, exhibited better performance than the other devices, which is attributed to induction of more balanced charge carriers and carrier recombination in the emissive layer. Copyright

Photoinduced energy and electron transfer in phenylethynyl-bridged zinc porphyrin-oligothienylenevinylene-C60 ensembles

Donor-bridge-acceptor triad (Por-2TV-C60) and tetrad molecules ((Por)2-2TV-C60), which incorporated C60 and one or two porphyrin molecules that were covalently linked through a phenylethynyl-oligothienylenevinyl

Chemical synthesis and evaluation of 17α-alkylated derivatives of estradiol as inhibitors of steroid sulfatase

Steroid sulfatase (STS) controls the levels of 3-hydroxysteroids available from circulating steroid sulfates in several normal and malignant tissues. This and the known involvement of active estrogens and androgens in diseases such as breast and prostate cancers thus make STS an interesting therapeutic target. Here we describe the chemical synthesis and characterization of an extended series of 17α-derivatives of estradiol (E2) using different strategies. A variant of the samarium-Barbier reaction with stoichiometric samarium metal and catalytic Kagan reagent formation was used for introducing low reactive benzyl substrates in position 17 of estrone (E1) whereas heterocyclic substrates were metalated and reacted with either the carbonyl or the 17-oxirane of E1. In vitro evaluation of the inhibitory potency of the new compounds against STS identified new inhibitors and allowed a more complete structure-activity relationship study of this family of 17α-derivatives of E2.

An easy and multigram-scale synthesis of versatile AA- and AB-type w-terphenylenes as building blocks for kinked polyphenylenes

A set of m-terphenylenes having a readily functionalizable hydroxy group as well as either symmetric AA-type or unsymmetric AB-type halide termini have been prepared on a several-gram scale. The synthesis was carried out on the basis of the Suzuki-Miyaura

Novel compounds, their preparation and use

Novel compounds of the general formula (I), in which the variables are as defined in claim 1, the use of these compounds as pharmaceutical compositions, pharmaceutical compositions comprising the compounds and methods of treatment employing these compound

(3-HYDROXY-4-AMINO-BUTAN-2-YL) -3- (2-THIAZOL-2-YL-PYRROLIDINE-1-CARBONYL) BENZAMIDE DERIVATIVES AND RELATED COMPOUNDS AS BETA-SECRETASE INHIBITORS FOR TREATING

The present invention provides novel beta-secretase inhibitors and methods for their use, including methods of treating of Alzheimer's disease. (Formula)

NOVEL COMPOUNDS, THEIR PREPARATION AND USE

Novel compounds of the general formula (I), in which the variables are as defined in claim 1, the use of these compounds as pharmaceutical compositions, pharmaceutical compositions comprising the compounds and methods of treatment employing these compound